文献速递胃肠外科围术期管理与 ERAS

减重手术术前胃镜异常发现及预测模型开发

Impact of preoperative esophagogastroduodenoscopy in patients undergoing bariatric surgery and development of a model to predict clinically significant abnormal endoscopic findings.
PubMed 文献 · Surg Endosc · 2022-07-21

该回顾性研究纳入2012年1月至2020年7月接受减重手术前胃镜检查的461例患者,评估上消化道异常患病率及需改变手术方案或延迟手术的预测因素。结果显示42.5%患者胃镜正常,21.9%需改变手术方案或延迟手术,男性及NSAID使用是显著相关因素,2型糖尿病为保护因素,并基于≥40岁亚组构建了预测模型(C-statistics 0.737)。

要点

  • 减重术前胃镜异常患病率高,21.9%需改变手术方案或延迟手术。
  • 男性及NSAID使用与需改变手术方案的病变显著相关。
  • ≥40岁患者可用列线图预测需改变手术方案的病变。

核心结论

  • 泰国减重手术患者术前胃镜异常发现患病率高,术前胃镜筛查有助于发现需改变手术决策的上消化道异常。
  • 新列线图可能有助于合理利用减重术前胃镜。

研究设计与样本

  • 回顾性队列研究,回顾2012年1月至2020年7月减重术前接受胃镜检查的患者病历。
  • 共纳入461例患者,女性占63.8%,平均年龄35.1±11.2岁,平均BMI 47.7±8.7 kg/m2。

主要发现

  • 胃镜结果分组1(正常)、2(异常但无需改变手术管理)、3(异常需改变手术方案或延迟手术)、4(手术禁忌)的患病率分别为42.5%、35.6%、21.9%、0%。
  • 最常见异常为非糜烂性胃炎(31.2%),其次为幽门螺杆菌感染(18.7%)和食管裂孔疝(10.2%)。
  • 单因素和多因素分析均显示男性及NSAID使用与组3病变检出显著相关,多因素分析显示2型糖尿病为显著保护因素。
  • 在≥40岁患者亚组中,多因素分析显示年龄、BMI和NSAID使用与组3病变检出显著相关,2型糖尿病仍为显著保护因素。

关键数值与推荐

  • 基于≥40岁亚组构建的列线图预测组3病变,C-statistics为0.737(95% CI 0.721‒0.752)。

临床怎么用

  • 减重手术前应行胃镜筛查以发现可能改变手术方案的上消化道异常。
  • 对于≥40岁患者,可参考列线图评估需改变手术方案的病变风险,合理选择术前胃镜。

局限性

  • 本研究为回顾性单中心研究,结果外推需谨慎。
  • 列线图仅在≥40岁亚组中开发并验证,尚未在全体人群或外部人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative esophagogastroduodenoscopy (EGD) in patients undergoing bariatric surgery can help surgeons detect abnormalities in the upper gastrointestinal (UGI) tract that may require a change in surgical plan. However, the need for EGD before bariatric surgery is controversial. OBJECTIVES: We aimed to determine the prevalence of UGI abnormalities and evaluate the predictive factors of abnormal findings that require a change in surgical plan or cause a delay in surgical treatment in patients undergoing bariatric surgery and develop a prediction model. METHODS: The medical records from January 2012 to July 2020 were retrospectively reviewed in patients who underwent EGD before bariatric surgery. The EGD findings were classified into four groups based on their effects on management. Group 1 had normal findings. Group 2 had abnormal findings that did not require a change in surgical management. Group 3 had abnormal findings that required a change in the surgical plan or caused a delay in surgical treatment. Group 4 had contraindications to surgery. Predictive factors for Groups 3 and 4 were analyzed using univariate and multivariate analyses. A model visualized as a nomogram was developed based on significant factors. Discrimination and calibration were evaluated. RESULTS: A total of 461 patient records (63.8% female) were reviewed. The mean age was 35.1 ± 11.2 years and the mean BMI was 47.7 ± 8.7 kg/m2. The prevalence of endoscopic findings in Groups 1, 2, 3, and 4 were 42.5%, 35.6%, 21.9%, and 0%, respectively. The most common abnormal findings were non-erosive gastritis (31.2%) followed by Helicobacter pylori infection (18.7%) and hiatal hernia (10.2%). Male sex and NSAID use were significantly associated with detection of lesions in Group 3 either on univariate or multivariate analysis, while type 2 diabetes mellitus (T2DM) was a significant protective factor on multivariate analysis. On subgroup analysis in patients ≥ 40 years old, multivariate analysis revealed age, BMI, and NSAID use were significantly associated with the detection of lesions in Group 3, while T2DM was still a significant protective factor. A nomogram to predict lesions in Group 3 for this subgroup was developed and showed good discrimination (C-statistics 0.737, 95% CI 0.721‒0.752). CONCLUSION: A high prevalence of abnormal endoscopic findings was observed in Thai patients who are undergoing bariatric surgery. Preoperative EGD screening is helpful in detecting UGI abnormalities that require a change in the surgical decision plan. The new nomogram may help rational utilization of EGD prior to bariatric surgery.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Sawathanon S, Promchan D, Thongwong M, et al. Impact of preoperative esophagogastroduodenoscopy in patients undergoing bariatric surgery and development of a model to predict clinically significant abnormal endoscopic findings. Surg Endosc. 2022. PMID: 35864356. doi:10.1007/s00464-022-09391-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。